---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250709"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:13:01.174344+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics prices upsized public offering of 4.18M shares at $5.50, raising ~$23M

## Summary
- Offering of 3,636,364 shares (base) plus full exercise of 545,454 over-allotment, all at $5.50/share.
- Gross proceeds of approximately $23.0 million; net proceeds for working capital and clinical development.
- Directors and officers subject to lock-up restricting share sales until January 22, 2026.
- Financial advisor to receive 100,000 warrants at $5.50 exercise price and $200,000 fee.
- Lucid Capital Markets is sole book-runner; Allele Capital Partners acted as financial advisor.

## SEC filing metadata
- accession: 0001193125-25-250709
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312525250709/0001193125-25-250709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312525250709/d52085d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250709
- JSON: https://secwatch.observer/filing/0001193125-25-250709.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.